​

AbCellera Biologics (ABCL) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

AbCellera Biologics Revenue Highlights

Latest Revenue (Y)

$28.83M

Latest Revenue (Q)

$8.96M

Main Segment (Y)

Research Fees

Main Geography (Y)

CANADA

AbCellera Biologics Revenue by Period

AbCellera Biologics Revenue by Year

DateRevenueChange
2024-12-31$28.83M-24.17%
2023-12-31$38.02M-92.17%
2022-12-31$485.42M29.38%
2021-12-31$375.20M60.92%
2020-12-31$233.16M1907.96%
2019-12-31$11.61M31.49%
2018-12-31$8.83M-

AbCellera Biologics generated $28.83M in revenue during NA 2024, up -24.17% compared to the previous quarter, and up 248.31% compared to the same period a year ago.

AbCellera Biologics Revenue by Quarter

DateRevenueChange
2025-09-30$8.96M-47.58%
2025-06-30$17.08M303.40%
2025-03-31$4.24M-16.14%
2024-12-31$5.05M-22.39%
2024-09-30$6.51M-11.14%
2024-06-30$7.32M-26.43%
2024-03-31$9.95M8.44%
2023-12-31$9.18M39.10%
2023-09-30$6.60M-34.38%
2023-06-30$10.06M-17.52%
2023-03-31$12.19M-43.41%
2022-12-31$21.55M-78.75%
2022-09-30$101.38M120.80%
2022-06-30$45.92M-85.50%
2022-03-31$316.58M127.22%
2021-12-31$139.33M2429.61%
2021-09-30$5.51M-80.07%
2021-06-30$27.64M-86.37%
2021-03-31$202.74M-2.49%
2020-12-31$207.91M2120.77%
2020-09-30$9.36M-16.62%
2020-06-30$11.23M141.10%
2020-03-31$4.66M45.42%
2019-12-31$3.20M-7.20%
2019-09-30$3.45M39.20%
2019-06-30$2.48M-0.00%
2019-03-31$2.48M-

AbCellera Biologics generated $8.96M in revenue during Q3 2025, up -47.58% compared to the previous quarter, and up 122.29% compared to the same period a year ago.

AbCellera Biologics Revenue Breakdown

AbCellera Biologics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22Dec 21
License$1.05M$969.00K$696.00K$20.78M
Milestone Payments$1.50M$1.50M$900.00K$8.00M
Research Fees$26.28M$35.56M$40.80M$19.08M
Royalty--$443.00M$327.30M

AbCellera Biologics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Research Fees (91.16%), Milestone Payments (5.20%), and License (3.64%).

Quarterly Revenue by Product

Product/ServiceSep 25Jun 25Mar 25Dec 24Sep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
License$138.00K$10.45M$167.00K$651.00K$218.00K$180.00K$185.00K$186.00K$226.00K$372.00K$165.00K$154.00K$147.00K$231.00K$86.00K$190.00K$263.00K$20.26M
Research Fees$8.82M$6.64M$4.07M$10.22M$6.29M$9.77M$8.74M$6.41M$9.83M$10.57M$11.42M$7.51M$12.54M$9.33M$4.75M$5.13M$5.21M$3.99M
Milestone Payments------$250.00K--$1.25M$500.00K$400.00K--$1.00M$7.00M--
Royalty----------$9.46M$93.32M$33.23M$307.02M$134.50M$190.00K$21.16M$171.50M

AbCellera Biologics's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: Research Fees (98.46%), and License (1.54%).

AbCellera Biologics Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 24Dec 23Dec 22Dec 21
CANADA$26.20M$36.00M$484.20M$353.40M
UNITED STATES$2.70M$2.00M$1.20M$21.80M

AbCellera Biologics's latest annual revenue breakdown by geography, as of Dec 24: CANADA (90.66%), and UNITED STATES (9.34%).

AbCellera Biologics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
XERSXeris Biopharma$163.91M$71.54M
ABCLAbCellera Biologics$28.83M$8.96M
JANXJanux Therapeutics$10.59M$10.00M
IMNMImmunome$9.04M-
NUVBNuvation Bio$7.87M$13.12M
CLDXCelldex Therapeutics$7.02M-
SIONSionna Therapeutics--
PHVSPharvaris--
SYRESpyre Therapeutics--
VERAVera Therapeutics--
BHVNBiohaven--

ABCL Revenue FAQ

What is AbCellera Biologics’s yearly revenue?

AbCellera Biologics's yearly revenue for 2024 was $28.83M, representing a decrease of -24.17% compared to 2023. The company's yearly revenue for 2023 was $38.02M, representing a decrease of -92.17% compared to 2022. ABCL's yearly revenue for 2022 was $485.42M, representing an increase of 29.38% compared to 2021.

What is AbCellera Biologics’s quarterly revenue?

AbCellera Biologics's quarterly revenue for Q3 2025 was $8.96M, a -47.58% decrease from the previous quarter (Q2 2025), and a 37.62% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $17.08M, a 303.40% increase from the previous quarter (Q1 2025), and a 133.29% increase year-over-year (Q2 2024). ABCL's quarterly revenue for Q1 2025 was $4.24M, a -16.14% decrease from the previous quarter (Q4 2024), and a -57.45% decrease year-over-year (Q1 2024).

What is AbCellera Biologics’s revenue growth rate?

AbCellera Biologics's revenue growth rate for the last 3 years (2022-2024) was -94.06%, and for the last 5 years (2020-2024) was -87.63%.

What are AbCellera Biologics’s revenue streams?

AbCellera Biologics's revenue streams in c 24 are License, Milestone Payments, and Research Fees. License generated $1.05M in revenue, accounting 3.64% of the company's total revenue, up 8.26% year-over-year. Milestone Payments generated $1.5M in revenue, accounting 5.20% of the company's total revenue Research Fees generated $26.28M in revenue, accounting 91.16% of the company's total revenue, down -26.08% year-over-year.

What is AbCellera Biologics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of AbCellera Biologics was Research Fees. This segment made a revenue of $26.28M, representing 91.16% of the company's total revenue.